United Therapeutics Co. (NASDAQ:UTHR) Stake Lifted by Toth Financial Advisory Corp

Toth Financial Advisory Corp increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,070 shares of the biotechnology company’s stock after buying an additional 180 shares during the quarter. Toth Financial Advisory Corp’s holdings in United Therapeutics were worth $1,083,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. World Investment Advisors LLC bought a new position in United Therapeutics in the 3rd quarter worth about $139,206,000. FMR LLC grew its position in United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares during the last quarter. Assetmark Inc. grew its position in United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its stake in shares of United Therapeutics by 32.5% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 343,744 shares of the biotechnology company’s stock worth $123,181,000 after purchasing an additional 84,369 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on UTHR shares. HC Wainwright increased their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH increased their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Argus increased their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, The Goldman Sachs Group increased their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $378.36.

United Therapeutics Stock Performance

United Therapeutics stock opened at $370.83 on Friday. The company has a 50 day moving average price of $365.19 and a 200 day moving average price of $355.61. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm has a market capitalization of $16.56 billion, a price-to-earnings ratio of 16.29, a P/E/G ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter last year, the business posted $5.38 EPS. The company’s revenue was up 22.9% on a year-over-year basis. Equities analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, Director Judy D. Olian sold 1,750 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the transaction, the director now owns 5,655 shares in the company, valued at $2,332,574.40. The trade was a 23.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Nilda Mesa sold 224 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $412.28, for a total value of $92,350.72. Following the sale, the director now directly owns 5,783 shares of the company’s stock, valued at $2,384,215.24. This trade represents a 3.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 146,848 shares of company stock worth $55,165,099. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.